Korolenko T A, Poteryaeva O N, Falameeva O V, Levina O A
Institute of Physiology, Siberian Division of Russian Academy of Medical Sciences, Novosibirsk.
Bull Exp Biol Med. 2003 Jul;136(1):46-8. doi: 10.1023/a:1026084712399.
The concentration of stefin A (cystatin A in mice) was measured in animals with experimental tumors (LS lymphosarcoma, HA-1-hepatoma, and Lewis lung carcinoma) during effective antitumor therapy. In mice with these tumors serum concentrations of stefin A increased, while the concentration of cystatin C (extracellular cystein proteinase inhibitor) decreased. The concentration of stefin A in tumor tissue in Lewis lung carcinoma was higher than in LS lymphosarcoma and HA-1-hepatoma ascitic cells, which can be explained by the degree of their malignancy. The content of stefin A in tumor tissue was similar to that in the liver and spleen of tumor-bearing animals, while its concentration in the liver and spleen of tumor-bearing animals was lower than in intact mice. The level of stefin A is an important marker of malignancy and an indicator of the efficiency of antitumor therapy.
在进行有效抗肿瘤治疗期间，对患有实验性肿瘤（LS淋巴肉瘤、HA-1肝癌和Lewis肺癌）的动物体内的stefin A（小鼠中的胱抑素A）浓度进行了测定。患有这些肿瘤的小鼠血清中stefin A浓度升高，而胱抑素C（细胞外半胱氨酸蛋白酶抑制剂）浓度降低。Lewis肺癌肿瘤组织中stefin A的浓度高于LS淋巴肉瘤和HA-1肝癌腹水细胞中的浓度，这可以用它们的恶性程度来解释。肿瘤组织中stefin A的含量与荷瘤动物肝脏和脾脏中的含量相似，而荷瘤动物肝脏和脾脏中其浓度低于正常小鼠。stefin A水平是恶性程度的重要标志物和抗肿瘤治疗效果的指标。
